EGFR-mutant lung adenocarcinoma with leptomeningeal metastasis after osimertinib treatment: intrathecal chemotherapy combined with targeted therapy supported by cerebrospinal fluid next generation sequencing — a case report
EGFR-mutiertes Lungenadenokarzinom mit Leptomeningealmetastasen nach Osimertinib: intrathekale Chemotherapie kombiniert mit zielgerichteter Therapie gestützt durch Liquor-Next-Generation-Sequencing – Fallbericht
Frontiers in Oncology · 04.11.2026 · 16
DOI: 10.3389/fonc.2026.1983545 ↗Auf einen Blick
Fallbericht einer 57-jährigen Patientin mit EGFR p.L858R-mutiertem Lungenadenokarzinom und zytologie-negativer Leptomeningealmetastasierung. Liquor-NGS stützte die Diagnose; unter intrathekaler Methotrexatgabe plus Osimertinib besserten sich die neurologischen Symptome.
Fragestellung
Wie kann Liquor-Next-Generation-Sequencing bei zytologie-negativer Leptomeningealmetastasierung nach Osimertinib die Diagnose und weitere Therapie unterstützen?
Methode
Fallbericht; nach 18 Monaten Osimertinib traten Symptome auf, MRT und Liquoruntersuchungen wurden durchgeführt; zusätzlich Liquor-NGS.
Ergebnisse
Drei Liquorzytologien blieben negativ. Liquor-NGS zeigte die EGFR-p.L858R-Mutation wie im Primärtumor sowie CDK4-Amplifikation. Unter intrathekaler Methotrexatgabe plus weiterem Osimertinib besserten sich Symptome und Liquordruck.
Einschränkungen
Einzelner Fallbericht; spätere Hirnparenchymmetastasen traten auf; unter multimodaler Therapie kamen Grad-3-Thrombozytopenie und schwere Mangelernährung vor.
Schlussfolgerung der Autor:innen
Liquor-NGS kann die diagnostische Hürde bei zytologie-negativer Leptomeningealmetastasierung überwinden und Resistenzalterationen sowie potenzielle Ziele für weitere zielgerichtete Strategien aufzeigen.
Kernaussagen
- 3 Liquorzytologien blieben trotz LM-Verdacht negativ
- Liquor-NGS zeigte EGFR p.L858R und CDK4-Amplifikation
- Symptomverbesserung unter intrathekaler Methotrexatgabe plus Osimertinib
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fallbericht in der Zeitschrift Frontiers in Oncology, online erschienen am 04.11.2026. Verfasst von Xinli Gan und 4 weiteren Autor:innen. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Leptomeningeal metastasis (LM) is a severe complication of advanced non-small cell lung cancer (NSCLC). Conventional cerebrospinal fluid (CSF) cytology has limited sensitivity and often delays diagnosis. We report a case of LM molecularly supported by CSF next-generation sequencing (NGS) after three negative cytological examinations. NGS also revealed a potential bypass resistance alteration that informed subsequent treatment considerations. Case A 57-year-old female never-smoker had EGFR exon 21 p.L858R-mutant lung adenocarcinoma. After 18 months of first-line osimertinib (80 mg once daily), she developed progressive nausea, vomiting, and dizziness. Contrast-enhanced cranial magnetic resonance imaging (MRI) showed linear leptomeningeal enhancement. Lumbar puncture showed markedly elevated intracranial pressure (>300 mmH2O) and increased CSF protein. However, three CSF cytological examinations (including cell block sections) found no malignant cells. CSF NGS detected the EGFR p.L858R mutation identical to the primary tumor, together with CDK4 amplification. Integrated with the clinical and MRI presentation, these findings supported a diagnosis of probable LM and suggested cell-cycle bypass activation as a potential mechanism associated with osimertinib resistance. After intrathecal methotrexate plus continued oral osimertinib, her neurological symptoms improved markedly, and intracranial pressure returned to normal. The first seizure occurred on March 19, 2026, and MRI on April 8, 2026 confirmed new brain parenchymal metastases. Whole-brain radiotherapy with a local boost to the metastases, antiepileptic treatment, and continued osimertinib led to obvious shrinkage of the intracranial lesions. Grade 3 thrombocytopenia and severe malnutrition occurred during multimodal therapy and improved with supportive care. At the last follow-up, the patient was clinically stable with an Eastern Cooperative Oncology Group performance status (ECOG PS) of 1.
Conclusions
CSF NGS can overcome the diagnostic bottleneck of cytology-negative LM. It can also identify potential resistance alterations and actionable targets (such as CDK4/6 inhibitors) at the same time, providing direction for subsequent targeted strategies. As part of multimodal therapy, intrathecal chemotherapy combined with an EGFR tyrosine kinase inhibitor (TKI) can contribute to disease control in the CSF compartment, whereas parenchymal progression still requires salvage radiotherapy. Cumulative hematological and nutritional toxicity should be monitored during sequential multimodal therapy.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Gan, X., Jin, X., Pan, M., Guo, Y., & Yang, C. (2026). EGFR-mutant lung adenocarcinoma with leptomeningeal metastasis after osimertinib treatment: intrathecal chemotherapy combined with targeted therapy supported by cerebrospinal fluid next generation sequencing — a case report. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1983545
Vancouver
Gan X, Jin X, Pan M, Guo Y, Yang C. EGFR-mutant lung adenocarcinoma with leptomeningeal metastasis after osimertinib treatment: intrathecal chemotherapy combined with targeted therapy supported by cerebrospinal fluid next generation sequencing — a case report. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1983545
BibTeX
@article{Gan2026,
author = {Gan, Xinli and Jin, Xin and Pan, Mingmei and Guo, Yan and Yang, Chunjiao},
title = {EGFR-mutant lung adenocarcinoma with leptomeningeal metastasis after osimertinib treatment: intrathecal chemotherapy combined with targeted therapy supported by cerebrospinal fluid next generation sequencing — a case report},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1983545}
}
EUVIMED